Abstract: The present invention is directed to methods for the growth, enrichment and isolation of microbes within a sample for further use in presumptive identification of pathogenic bacteria that may therein be contained.

Abstract: The present invention provides for a method of implementing fluorescent in situ hybridization (FISH) or other cellular analysis processes using intact cells within a microfluidic, chip-based, apparatus. The invention further provides for a method of cellular immobilization within a microfluidic device. Also provided is a method for automated analysis of FISH or other cellular analysis using discrete colormetric probes.

Abstract: Embodiments provide cell culture methods to produce a 3-D model assembly that mimics in vitro the microenvironment of human bone marrow, where cells occupy distinct niches. Methods and apparatuses are provided for the efficient testing of cancer, including malignant hematopoietic cancers and metastatic spread to the bone marrow of solid tumors, and of other diseases of the blood and bone marrow. Methods and apparatuses are further provided in embodiments for the investigation of bone marrow cell biological characteristics and for the testing of therapeutics for nonmalignant diseases of the blood and bone marrow.

Abstract: Provided for are three novel isoenzyme variants of the human Hyaluronan Synthase gene, HAS1Va, HAS1Vb, and HAS1Vc. Also provided is a method for assessing disease, or susceptibility to disease, in a patient; in which a cell or sample of a cell population is mixed with at least one compound which specifically binds to HAS1Va, HAS1Vb, HAS1Vc or HAS2 isoenzyme or isoenzyme variant genomic mRNA transcript or products arising therefrom; and methods of treatment.

Abstract: The present invention provides for methods for detection of cancer or predisposition to cancer comprising detection of specific mutations in genomic DNA encoding the HAS1 protein. The present invention further provides for methods for monitoring of disease progression in a mammalian patient and novel therapeutic methodologies for treatment of disease.

Abstract: The invention provides a method to alter elimination kinetics of hyaluronic acid (HA) in a patient is disclosed. Administration of HA to a patient, followed by at least one subsequent administration results in an alteration of the ability of the patient to eliminate HA. Also disclosed is a method for upregulating, and/or increasing the affinity of cellular HA receptors. Also disclosed are methods for increasing the ability of cells to bind HA improved imaging of cells and tissues, determination of the existence of disease in a patient.

Abstract: The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CFS of G-CSF.

Abstract: The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CSF or G-CSF.

Abstract: The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CSF or G-CSF.

Abstract: Provided for are three novel isoenzyme variants of the human Hyaluronan Synthase gene, HAS1Va, HAS1Vb, and HAS1Vc. Also provided is a method for assessing disease, or susceptibility to disease, in a patient; in which a cell or sample of a cell population is mixed with at least one compound which specifically binds to HAS1Va, HAS1Vb, HAS1Vc or HAS2 isoenzyme or isoenzyme variant genomic mRNA transcript or products arising therefrom; and methods of treatment.